Evidence mapPaperPMID 41769258Full record

ArticleBio-protocol2026

In Ovo CAM-Based Xenograft Model for Investigating Tumor Developmental Biology in Breast Cancer.

Carlos César Patiño Morales, Claudia Haydée González de La Rosa, Ricardo Jaime-Cruz, Marcela Salazar-García, Laura Villavicencio Guzmán, Ana Karen Herrera-Vargas

Abstract read
In one paragraph

Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carlos César Patiño MoralesDepartamento de Ciencias Naturales, Unidad Cuajimalpa, Universidad Autónoma Metropolitana, Ciudad de México, México.
Claudia Haydée González de La RosaDepartamento de Ciencias Naturales, Unidad Cuajimalpa, Universidad Autónoma Metropolitana, Ciudad de México, México.
Ricardo Jaime-CruzLaboratorio de Investigación en Biología del Desarrollo y Teratogénesis Experimental/Hospital Infantil de México Federico Gómez, Mexico City, México.
Marcela Salazar-GarcíaLaboratorio de Investigación en Biología del Desarrollo y Teratogénesis Experimental/Hospital Infantil de México Federico Gómez, Mexico City, México.
Laura Villavicencio GuzmánLaboratorio de Investigación en Biología del Desarrollo y Teratogénesis Experimental/Hospital Infantil de México Federico Gómez, Mexico City, México.
Ana Karen Herrera-VargasLaboratorio de Biología Celular del Cáncer/ Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains one of the most prevalent and deadly malignancies affecting women worldwide. Its progression and metastatic behavior are driven by complex mechanisms. To develop more effective therapeutic strategies, it is crucial to understand tumor growth, angiogenesis, and microenvironmental interactions. Although traditional in vivo models such as murine xenografts have long been used to study tumor biology, these approaches are often time-consuming, costly, and ethically constrained. In contrast, the chick embryo chorioallantoic membrane (CAM) assay offers a rapid, cost-effective, and ethically flexible alternative for evaluating tumor development and angiogenesis. This protocol describes an in ovo CAM-based xenograft model in which human breast cancer cells are implanted onto the vascularized CAM of chick embryos. This method enables real-time evaluation of tumor growth. Furthermore, the model allows for manipulation of experimental conditions, including pharmacological treatments or genetic modifications, to study specific molecular mechanisms involved in breast cancer progression. The major advantages of this protocol lie in its simplicity, reduced cost, and capacity for high-throughput screening, making it a valuable tool for translational cancer research. Key features • Enables rapid tumor formation (3-4 days) after implantation of breast cancer cells. • Ethical and low-cost alternative to rodent xenograft models; suitable for laboratories without animal facility infrastructure and aligned with the 3Rs principles. • Optimized for short-term studies of tumor development, angiogenesis, and early metastatic events. • Highly suitable for pharmacological testing and experimental manipulation of the tumor microenvironment.

Indexed as

Breast cancerCAM assayChick embryoIn ovo modelXenograft

Identifiers

PMID41769258
PMCPMC12936518

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.